1-3 of 3
Mireia Camos, MD
Close
Sort by
Journal Articles

Molecular Markers Predicting Clinical Outcome in Patients with Intermediate-Risk Acute Myeloid Leukemia Receiving Autologous Stem Cell Transplantation.

Jordi Esteve, MD, Susana Kalko, PhD, Montserrat Torrebadell, MD, Mireia Camos, MD, Pedro Jares, PhD, Maria Rozman, MD, Marta Pratcorona, MD, Salut Brunet, MD, Josep Nomdedeu, MD, Ana Carrio, PhD, Dolors Costa, PhD, Emili Montserrat, MD
Journal: Blood
Blood (2007) 110 (11): 604.
https://doi.org/10.1182/blood.V110.11.604.604
Published: 2007
Journal Articles

Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.

Mireia Camos, MD, Jordi Esteve, MD, Dolors Colomer, PhD, Pedro Jares, PhD, Maria Rozman, MD, Neus Villamor, MD, Dolors Costa, PhD, Ana Carrio, PhD, Josep F. Nomdedeu, MD, Emili Montserrat, MD, Elias Campo, PhD
Journal: Blood
Blood (2005) 106 (11): 3009.
https://doi.org/10.1182/blood.V106.11.3009.3009
Published: 2005
Journal Articles

Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.

Armando Lopez-Guillermo, MD, Santiago Mercadal, MD, Javier Briones, MD, Blanca Xicoy, MD, Carme Pedro, MD, Lourdes Escoda, MD, Cristina Estany, MD, Mireia Camos, MD, Josep Maria Ribera, MD, Rodrigo Martino, MD, Emilio Montserrat, MD
Journal: Blood
Blood (2005) 106 (11): 2077.
https://doi.org/10.1182/blood.V106.11.2077.2077
Published: 2005